Benitec Biopharma
BNTC
6 hedge funds and large institutions have $1.05M invested in Benitec Biopharma in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
31% more capital invested
Capital invested by funds: $797K → $1.05M (+$249K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$22.8K |
| 2 |
Morgan Stanley
New York
|
+$1.72K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$6.9K |
| 2 |
AIC
Ameritas Investment Company
Lincoln,
Nebraska
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highbridge Capital Management
New York
| $527K | -$6.9K | -16 | -1% |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $228K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $135K | +$22.8K | +53 | +23% |
|
|
4
Morgan Stanley
New York
| $126K | +$1.72K | +4 | +2% |
|
5
Renaissance Technologies
New York
| $27K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | +$1.29K | +3 | +100% |
|
|
AIC
7
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$3K | -8 | Closed |
|
BNTC Hedge Fund Activity: Q1 2019 in Review
6 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2019, worth a combined $1.05M — up 31% from $797K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BNTC and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $22.8K. The largest seller was Highbridge Capital Management, cutting an estimated $6.9K.
- 6 institutional investors held Benitec Biopharma (BNTC) as of Q1 2019, down from 7 in Q4 2018.
- Funds reported $1.05M of Benitec Biopharma stock for Q1 2019, up 31% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest Benitec Biopharma buyer in Q1 2019 was Susquehanna International Group, an estimated $22.8K added.
- The largest Benitec Biopharma seller in Q1 2019 was Highbridge Capital Management, an estimated $6.9K sold.
Based on aggregated 13F filings for Q1 2019.